---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050695"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:47:43.983405+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MIRA submits IND for Ketamir-2 (neuropathic pain) to FDA; Phase I expected Q1 2025

## Summary
- IND submitted to FDA on Dec 19, 2024 for Ketamir-2, a novel oral ketamine analog.
- Phase I clinical trials expected to start Q1 2025; Phase IIa planned for late 2025.
- Preclinical data showed full pain reversal with no adverse safety findings.
- Ketamir-2 targets unmet needs in neurological disorders and neuropathic pain.

## SEC filing metadata
- accession: 0001493152-24-050695
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224050695/0001493152-24-050695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224050695/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050695
- JSON: https://secwatch.observer/filing/0001493152-24-050695.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.